MaxCyte, Inc.
MXCTMaxCyte, Inc. in brief
MaxCyte, Inc. is a listed company in the Diagnostics and Research industry, based in Rockville, Maryland, USA. It was founded in 1998. Its market value was $156 M on 27 October 2026, which makes it the 17,164th largest listed company in the world and the 3,290th largest in the USA on this site. In the year to December 2025 it had sales of $33 M and a net loss of $45 M. It employs about 91 people and Maher Masoud is its chief executive. Its largest product and service lines by sales in 2025 were Licenses (37%) and Assay and other service revenue (6%). By market, the largest shares of its 2025 sales came from USA (64%). Its shares trade under the symbol MXCT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MaxCyte, Inc.
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells.
Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.
From the company's annual report filed with the US SEC: read the report
MaxCyte, Inc. timeline
- 1998
- 🏁· approximateIncorporated as Maxcyte, Inc.
- 2004
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- 📈· approximateListed on London Stock Exchange as MXCT
- •Legal Entity Identifier issuedLEI 54930053YHXULRFCU991 registered.
- 2021
- 📈· approximateListed on Nasdaq as MXCT
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 30 July 2021; shares registered for exchange trading on 27 July 2021.
- 2022
- 💰Record revenue of $44 millionFY2022, the highest of the 7 years on record.
- 📍Headquarters moved to 9713 Key West Avenue, Rockville
Events of MaxCyte, Inc. from the GLEIF LEI register, SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,632 (Jan 2022) · #2,580 (Dec 2022) · #2,766 (Jul 2023) · #2,582 (Jan 2024) · #1,995 (Mar 2026) · #3,267 (Aug 2026) · #3,438 (Oct 2026) · #3,294 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.5×
- Price / book
- 0.9×
- Free cash flow yield
- -23.2%
- Net margin (TTM)
- -81.4%
- Operating margin
- -157.1%
- Return on equity
- -16.3%
- Liabilities / assets
- 15.3%
- Revenue growth
- -14.5%
- R&D / revenue
- 63.0%
- Revenue per employee
- $363 K
- Profit per employee
- $-490 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $33M | -14.5% | $-52M | $-45M | -135.1% |
| Dec 2024 | $39M | -6.4% | $-51M | $-41M | -106.3% |
| Dec 2023 | $41M | -6.7% | $-48M | $-38M | -91.8% |
| Dec 2022 | $44M | +30.6% | $-27M | $-24M | -53.3% |
| Dec 2021 | $34M | +29.5% | $-18M | $-19M | -56.3% |
| Dec 2020 | $26M | +21.0% | $-11M | $-12M | -45.2% |
| Dec 2019 | $22M | — | $-12M | $-13M | -59.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-34M | $2M | $-36M | $-0.42 | — |
| Dec 2024 | $-28M | $2M | $-29M | $-0.39 | — |
| Dec 2023 | $-22M | $4M | $-25M | $-0.37 | — |
| Dec 2022 | $-15M | $18M | $-33M | $-0.23 | — |
| Dec 2021 | $-11M | $4M | $-15M | $-0.21 | — |
| Dec 2020 | $-9M | $2M | $-11M | $-0.17 | — |
| Dec 2019 | $-9M | $1M | $-10M | $-0.23 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $10M (+48.6% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportMaterial agreement · Results of operations · Unregistered share sale · Regulation FD disclosure
- Oct 14, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jun 17, 20268-KCurrent reportShareholder vote
- Jun 16, 20268-KCurrent reportListing notice
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 29, 2026DEF 14AProxy statement
- Mar 27, 20268-KCurrent reportDirectors or officers changed
- Mar 25, 202610-KAnnual report · period to Dec 2025
Official filings of MaxCyte, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $33 M
- Operating income
- $-52 M
- Net income
- $-45 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $203 M
- Total liabilities
- $31 M
- Total equity
- $171 M
As of December-2025
Top 100 institutional investors in MaxCyte, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Capricorn Fund Managers Ltd | 8,200,000 | 0 (0.00%) | 7.94% | $9 M | Nov 3, 2026 |
| 2 | Vitruvian Partners LLP | 5,043,356 | 0 (0.00%) | 4.88% | $6 M | Nov 13, 2026 |
| 3 | Liontrust Investment Partners LLP | 4,840,487 | New | 4.69% | $5 M | Nov 18, 2026 |
| 4 | Vanguard Capital Management LLC | 4,008,963 | -22,321 (-0.55%) | 3.88% | $4 M | Nov 13, 2026 |
| 5 | Morgan Stanley | 3,981,178 | +287,129 (+7.77%) | 3.86% | $4 M | Nov 13, 2026 |
| 6 | BlackRock, Inc. | 3,026,506 | -34,454 (-1.13%) | 2.93% | $3 M | Nov 13, 2026 |
| 7 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,773,554 | 0 (0.00%) | 2.69% | $3 M | Nov 13, 2026 |
| 8 | Cadian Capital Management, LP | 2,624,685 | +423,519 (+19.24%) | 2.54% | $3 M | Nov 16, 2026 |
| 9 | Two Sigma Investments, LP | 2,409,859 | +946,918 (+64.73%) | 2.33% | $3 M | Nov 16, 2026 |
| 10 | Mudita Advisors LLP | 2,260,201 | -1,110,488 (-32.95%) | 2.19% | $3 M | Nov 16, 2026 |
| 11 | Renaissance Technologies LLC | 2,035,300 | +124,500 (+6.52%) | 1.97% | $2 M | Nov 12, 2026 |
| 12 | Peapod Lane Capital LLC | 1,980,392 | -145,360 (-6.84%) | 1.92% | $2 M | Oct 22, 2026 |
| 13 | RBF Capital, LLC | 1,625,380 | +302,937 (+22.91%) | 1.57% | $2 M | Nov 13, 2026 |
| 14 | Brooklands Fund Management Ltd | 1,564,570 | -1,283,513 (-45.07%) | 1.52% | $2 M | Oct 28, 2026 |
| 15 | Marshall Wace, LLP | 1,562,275 | +547,497 (+53.95%) | 1.51% | $2 M | Nov 13, 2026 |
| 16 | Nano Cap New Millennium Growth Fund L P | 1,500,000 | +300,000 (+25.00%) | 1.45% | $2 M | Nov 13, 2026 |
| 17 | Geode Capital Management, LLC | 1,249,490 | -77,424 (-5.83%) | 1.21% | $1 M | Nov 6, 2026 |
| 18 | Citadel Advisors LLC | 1,145,207 | +288,889 (+33.74%) | 1.11% | $1 M | Nov 16, 2026 |
| 19 | Goldman Sachs Group Inc | 914,460 | -327,483 (-26.37%) | 0.89% | $1 M | Nov 16, 2026 |
| 20 | Gsa Capital Partners LLP | 890,654 | +334,710 (+60.21%) | 0.86% | $1 M | Nov 16, 2026 |
| 21 | Willis Investment Counsel | 862,758 | 0 (0.00%) | 0.84% | $1 M | Oct 20, 2026 |
| 22 | Millennium Management LLC | 689,847 | -515,074 (-42.75%) | 0.67% | $1 M | Nov 16, 2026 |
| 23 | Jane Street Group, LLC | 635,118 | -927,885 (-59.37%) | 0.62% | $1 M | Nov 12, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 610,650 | -42,553 (-6.51%) | 0.59% | $1 M | Nov 13, 2026 |
| 25 | Susquehanna International Group, LLP | 568,553 | +411,561 (+262.15%) | 0.55% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | State Street Corp | 484,150 | -32,600 (-6.31%) | 0.47% | $1 M | Nov 12, 2026 |
| 27 | AQR Capital Management LLC | 452,859 | -1,429,917 (-75.95%) | 0.44% | $1 M | Nov 16, 2026 |
| 28 | Arrowstreet Capital, Limited Partnership | 426,262 | New | 0.41% | $0 M | Nov 13, 2026 |
| 29 | Acadian Asset Management LLC | 415,933 | New | 0.40% | $0 M | Nov 9, 2026 |
| 30 | George Kaiser Family Foundation | 332,418 | -295,118 (-47.03%) | 0.32% | $0 M | Nov 16, 2026 |
| 31 | Jacobs Levy Equity Management, Inc | 313,294 | +43,029 (+15.92%) | 0.30% | $0 M | Nov 16, 2026 |
| 32 | Apollo Management Holdings, L.P. | 307,987 | 0 (0.00%) | 0.30% | $0 M | Nov 16, 2026 |
| 33 | Vanguard Portfolio Management LLC | 284,488 | +24,045 (+9.23%) | 0.28% | $0 M | Nov 13, 2026 |
| 34 | HSBC Holdings PLC | 273,819 | +118,018 (+75.75%) | 0.27% | $0 M | Nov 16, 2026 |
| 35 | Northern Trust Corp | 264,432 | -482 (-0.18%) | 0.26% | $0 M | Nov 16, 2026 |
| 36 | Dimensional Fund Advisors LP | 242,131 | -28,609 (-10.57%) | 0.23% | $0 M | Nov 4, 2026 |
| 37 | Russell Investments Group, Ltd. | 237,758 | +233,787 (+5887.36%) | 0.23% | $0 M | Nov 6, 2026 |
| 38 | Stonepine Capital Management, LLC | 224,881 | -526,725 (-70.08%) | 0.22% | $0 M | Nov 13, 2026 |
| 39 | Corient Private Wealth LP | 211,493 | New | 0.20% | $0 M | Nov 16, 2026 |
| 40 | Rathbones Group PLC | 200,841 | 0 (0.00%) | 0.19% | $0 M | Nov 12, 2026 |
| 41 | UBS Group AG | 188,683 | -95,590 (-33.63%) | 0.18% | $0 M | Nov 10, 2026 |
| 42 | Diametric Capital, LP | 183,120 | New | 0.18% | $0 M | Nov 16, 2026 |
| 43 | Bank Of America Corp /de/ | 181,245 | +80,529 (+79.96%) | 0.18% | $0 M | Nov 16, 2026 |
| 44 | Canada Pension Plan Investment Board | 177,600 | +141,900 (+397.48%) | 0.17% | $0 M | Nov 16, 2026 |
| 45 | FMR LLC | 175,037 | -5,301 (-2.94%) | 0.17% | $0 M | Nov 10, 2026 |
| 46 | Barclays PLC | 147,325 | -1,688 (-1.13%) | 0.14% | $0 M | Nov 6, 2026 |
| 47 | Callan Family Office, LLC | 143,068 | -11,243 (-7.29%) | 0.14% | $0 M | Nov 13, 2026 |
| 48 | Squarepoint Ops LLC | 134,027 | +119,183 (+802.90%) | 0.13% | $0 M | Nov 9, 2026 |
| 49 | Graham Capital Management, L.P. | 120,838 | New | 0.12% | $0 M | Nov 16, 2026 |
| 50 | Charles Schwab Investment Management Inc | 117,192 | 0 (0.00%) | 0.11% | $0 M | Nov 16, 2026 |
| 51 | Cabot Wealth Management Inc | 88,623 | 0 (0.00%) | 0.09% | $0 M | Nov 5, 2026 |
| 52 | Quadrature Capital Ltd | 84,875 | -20,641 (-19.56%) | 0.08% | $0 M | Nov 13, 2026 |
| 53 | BNP Paribas Financial Markets | 79,655 | +61,579 (+340.67%) | 0.08% | $0 M | Nov 12, 2026 |
| 54 | Schonfeld Strategic Advisors LLC | 79,402 | New | 0.08% | $0 M | Nov 16, 2026 |
| 55 | Ameriprise Financial Inc | 75,804 | -3,668 (-4.62%) | 0.07% | $0 M | Nov 16, 2026 |
| 56 | Point72 Asset Management, L.P. | 68,473 | -231,380 (-77.16%) | 0.07% | $0 M | Nov 16, 2026 |
| 57 | Granite Investment Partners, LLC | 66,315 | +48,852 (+279.75%) | 0.06% | $0 M | Nov 4, 2026 |
| 58 | Bridgeway Capital Management, LLC | 65,168 | New | 0.06% | $0 M | Nov 16, 2026 |
| 59 | Mackenzie Financial Corp | 62,518 | New | 0.06% | $0 M | Nov 2, 2026 |
| 60 | Tudor Investment Corp Et Al | 62,075 | -16,238 (-20.73%) | 0.06% | $0 M | Nov 16, 2026 |
| 61 | Vanguard Personalized Indexing Management, LLC | 61,128 | -1,864 (-2.96%) | 0.06% | $0 M | Nov 16, 2026 |
| 62 | Empowered Funds, LLC | 59,368 | New | 0.06% | $0 M | Nov 13, 2026 |
| 63 | Qube Research & Technologies Ltd | 55,509 | -333,593 (-85.73%) | 0.05% | $0 M | Nov 13, 2026 |
| 64 | Waverly Advisors, LLC | 50,533 | -3,481 (-6.44%) | 0.05% | $0 M | Nov 16, 2026 |
| 65 | Catalyst Funds Management Pty Ltd | 48,113 | -13,587 (-22.02%) | 0.05% | $0 M | Nov 12, 2026 |
| 66 | XTX Topco Ltd | 44,937 | -161,653 (-78.25%) | 0.04% | $0 M | Nov 16, 2026 |
| 67 | JMN Financial LLC | 41,839 | 0 (0.00%) | 0.04% | $0 M | Nov 10, 2026 |
| 68 | Vanguard Global Advisers, LLC | 41,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 69 | Cerity Partners LLC | 40,245 | -57,613 (-58.87%) | 0.04% | $0 M | Nov 13, 2026 |
| 70 | Bank of New York Mellon Corp | 32,458 | -47,882 (-59.60%) | 0.03% | $0 M | Nov 5, 2026 |
| 71 | SEI Investments Co | 29,700 | New | 0.03% | $0 M | Nov 10, 2026 |
| 72 | Kwmg, LLC | 25,833 | 0 (0.00%) | 0.03% | $0 M | Oct 7, 2026 |
| 73 | Tower Research Capital LLC (TRC) | 25,794 | -28,137 (-52.17%) | 0.03% | $0 M | Nov 16, 2026 |
| 74 | PNC Financial Services Group, Inc. | 21,871 | -1,139 (-4.95%) | 0.02% | $0 M | Nov 6, 2026 |
| 75 | Stifel Financial Corp | 20,628 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 76 | Mariner, LLC | 20,463 | -76,209 (-78.83%) | 0.02% | $0 M | Nov 12, 2026 |
| 77 | Bolton Securities Corporation | 19,958 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 78 | Man Group plc | 18,496 | -430,462 (-95.88%) | 0.02% | $0 M | Nov 16, 2026 |
| 79 | Spark Investment Management LLC | 18,100 | +2,200 (+13.84%) | 0.02% | $0 M | Nov 13, 2026 |
| 80 | R Squared Ltd | 16,289 | -3,491 (-17.65%) | 0.02% | $0 M | Nov 6, 2026 |
| 81 | Two Sigma Securities, LLC | 16,276 | New | 0.02% | $0 M | Nov 16, 2026 |
| 82 | Prelude Capital Management, LLC | 13,997 | New | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Blair William & Co/il | 12,500 | +431 (+3.57%) | 0.01% | $0 M | Nov 10, 2026 |
| 84 | Axq Capital, LP | 12,067 | New | 0.01% | $0 M | Nov 12, 2026 |
| 85 | Wealth Enhancement Advisory Services, LLC | 11,626 | -45,764 (-79.74%) | 0.01% | $0 M | Oct 13, 2026 |
| 86 | Citigroup Inc | 11,574 | +11,120 (+2449.34%) | 0.01% | $0 M | Nov 4, 2026 |
| 87 | Victory Capital Management Inc | 10,865 | -592 (-5.17%) | 0.01% | $0 M | Nov 10, 2026 |
| 88 | Arax Advisory Partners | 10,574 | -20,804 (-66.30%) | 0.01% | $0 M | Nov 12, 2026 |
| 89 | Jefferies Financial Group Inc. | 10,000 | -5,972 (-37.39%) | 0.01% | $0 M | Nov 5, 2026 |
| 90 | Nuveen, LLC | 9,047 | New | 0.01% | $0 M | Nov 10, 2026 |
| 91 | Diadema Partners LP | 8,190 | New | 0.01% | $0 M | Nov 16, 2026 |
| 92 | Persistent Asset Partners Ltd | 8,002 | New | 0.01% | $0 M | Nov 13, 2026 |
| 93 | Royal Bank Of Canada | 7,767 | -417 (-5.10%) | 0.01% | $0 M | Nov 16, 2026 |
| 94 | Optiver Holding B.V. | 7,730 | +7,727 (+257566.67%) | 0.01% | $0 M | Nov 16, 2026 |
| 95 | GAMMA Investing LLC | 5,702 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 96 | Employees Retirement System of Texas | 4,270 | New | 0.00% | $0 M | Nov 10, 2026 |
| 97 | TrinityBridge Ltd | 4,000 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 98 | Jpmorgan Chase & Co | 3,798 | +2,223 (+141.14%) | 0.00% | $0 M | Nov 12, 2026 |
| 99 | Bare Financial Services, Inc | 1,599 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 100 | Capital Analysts, LLC | 1,266 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding MaxCyte, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.74 M | $3 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.16 M | $1 M | 1.1% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 518,559 | $1 M | 0.50% | <0.01% | +4.0% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 394,028 | $0 M | 0.38% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc. | 347,433 | $0 M | 0.34% | 0.15% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 301,966 | $0 M | 0.29% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 211,975 | $0 M | 0.21% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 199,501 | $0 M | 0.19% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 164,501 | $0 M | 0.16% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 156,238 | $0 M | 0.15% | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 144,027 | $0 M | 0.14% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 109,790 | $0 M | 0.11% | <0.01% | +3.2% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 109,491 | $0 M | 0.11% | <0.01% | +197% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 114,828 | $0 M | 0.11% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 77,156 | $0 M | 0.07% | <0.01% | +4.8% | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 74,409 | $0 M | 0.07% | <0.01% | −23% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 57,279 | $0 M | 0.06% | <0.01% | +35% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 56,050 | $0 M | 0.05% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 46,791 | $0 M | 0.05% | <0.01% | −37% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 46,473 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 43,428 | $0 M | 0.04% | 0.01% | −45% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 40,960 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 37,160 | $0 M | 0.04% | 0.02% | −64% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 38,185 | $0 M | 0.04% | <0.01% | −0.3% | Jul 31, 2026 |
| 🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC | 22,645 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 22,321 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 20,500 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 18,521 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 18,120 | $0 M | 0.02% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 12,450 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 11,457 | $0 M | 0.01% | <0.01% | +1.5% | Jul 31, 2026 |
| 🇺🇸 Guardian Large Cap Fundamental Growth VIP FundPark Avenue Institutional Advisers LLC | 7,867 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 7,598 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 6,828 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 5,380 | $0 M | <0.01% | <0.01% | +115% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,758 | $0 M | <0.01% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 3,837 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,722 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,760 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 3,354 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 2,235 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 41 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at MaxCyte, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Maher MasoudPresident and CEO, Director | Buy | +100,000 | $1.208 | $121 K | 575,000 | Form 4 |
| filed | John Joseph JohnstonDirector | Grant or award | +30,421 | — | — | 201,581 | Form 4 |
| filed | Stanley C. ErckDirector | Grant or award | +30,421 | — | — | 428,749 | Form 4 |
| filed | Cynthia CollinsDirector | Grant or award | +30,421 | — | — | 111,310 | Form 4 |
| filed | Patrick J. BalthropDirector | Grant or award | +30,421 | — | — | 80,998 | Form 4 |
| filed | Rekha HemrajaniDirector | Grant or award | +30,421 | — | — | 70,314 | Form 4 |
| filed | Yasir B. Al-WakeelDirector | Grant or award | +30,421 | — | — | 80,998 | Form 4 |
| filed | William W. BrookeDirector | Grant or award | +30,421 | — | — | 181,300 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: MaxCyte, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $4M |
Fails to deliver
- : 1 shares at $1.51
- : 1 shares at $1.43
- : 1 shares at $1.30
- : 964 shares at $1.09
- : 964 shares at $1.08
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
MaxCyte, Inc. scorecard#
Passes 3 of the 20 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Diagnostics and Research's median of 3.7×.
- ✗Price to sales below its peers' median4.5×Price to sales 4.5× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-23.2%Free cash flow is -23.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-14.5%Revenue down 14.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-9.3%-9.3% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-9.3%-9.3% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.42 vs -0.39Diluted EPS -0.42 in fiscal 2025 against -0.39 the year before (report's currency).
- ✗Net income higher than five years earlier-$45 M-$45 M in fiscal 2025 against -$12 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$45 MNet income -$45 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-157.1%-157.1% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-23.6%-23.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-157.1%-157.1% in fiscal 2025 against -61.8% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities8.3×Current ratio 8.30 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.14Z-score 1.14 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.5%Diluted shares up 1.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from MaxCyte, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -157.1% | -2.4% | |
| Net margin | -135.1% | -3.6% | |
| Return on equity | -23.6% | -5.4% | |
| Revenue growth, 3 years a year | -9.3% | 3.6% | |
| Revenue growth | -14.5% | 6.6% | |
| Free cash flow margin | -109.5% | 4.7% |
2of 8on the Piotroski tests of financial strength
- Revenue fell 14.5% against the year before.
- Net loss of $45 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$36 million.
MaxCyte, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 33−14.5%100% | 39−6.4%100% | 41−6.7%100% | 44r44+30.6%100% | 34+29.5%100% | 26+21.0%100% | 22—100% | |
| Cost of revenue | 6.2−12.4%18.8% | 7.1+49.7%18.4% | 4.7−7.0%11.5% | 5.1r5.1+39.8%11.5% | 3.6+31.8%10.8% | 2.8+10.7%10.6% | 2.5—11.6% | |
| Gross profit | 27−15.0%81.2% | 32−13.7%81.6% | 37−6.7%88.5% | 39r39+29.5%88.5% | 30+29.2%89.2% | 23+22.4%89.4% | 19—88.4% | |
| Research and development | 21−6.3%63.1% | 22−6.7%57.5% | 24+22.1%57.7% | 20r20+26.7%44.1% | 15−13.1%45.5% | 18+0.8%67.8% | 18—81.4% | |
| Selling and marketing | 19−29.0%57.3% | 27−1.2%69.0% | 27+44.6%65.3% | 19r19+43.5%42.1% | 13+56.1%38.4% | 8.3+6.1%31.8% | 7.9—36.3% | |
| General and administrative | 28−5.3%85.1% | 30−1.2%76.9% | 30+16.4%72.8% | 26r26+38.3%58.4% | 19+153%55.1% | 7.4+32.7%28.2% | 5.6—25.7% | |
| Operating expenses | 79−4.9%238% | 83−2.5%214% | 85+27.5%205% | 67r67+37.3%150% | 48+40.6%143% | 34+9.2%132% | 32—146% | |
| Operating income | −52—−157% | −51—−133% | −48—−117% | −27r−27—−61.8% | −18—−53.7% | −11—−42.3% | −12—−57.4% | |
| Interest and finance income | 7.3−28.3%22.0% | 10−2.3%26.3% | 10+165%25.1% | 3.9r3.9+2497%8.8% | 0.2+129%0.4% | 0.1−68.0%0.3% | 0.2—1.0% | |
| Interest expense and finance costs | — | — | — | — | 0.0−75.1%0.0% | 0.0−58.2%0.1% | 0.1—0.2% | |
| Other non-operating income (expense) | 7.3−28.3%22.0% | 10−2.3%26.3% | 10+174%25.1% | 3.8r3.8—8.6% | −0.9—−2.6% | −0.8—−2.9% | −0.5—−2.2% | |
| Income before tax | −45—−135% | −41—−106% | −38—−91.8% | — | — | — | — | |
| Income tax | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −45—−135% | −41—−106% | −38—−91.8% | −24r−24—−53.3% | −19—−56.3% | −12—−45.2% | −13—−59.6% | |
| Net income attributable to shareholders | −45—−135% | −41—−106% | −38—−91.8% | −24r−24—−53.3% | −19—−56.3% | −12—−45.2% | −13—−59.6% | |
| Earnings per share, basic | -0.42—— | -0.39—— | -0.37—— | -0.23—— | -0.21—— | -0.17—— | -0.23—— | |
| Earnings per share, diluted | -0.42—— | -0.39—— | -0.37—— | -0.23—— | -0.21—— | -0.17—— | -0.23—— | |
| Shares, weighted average (basic) | 106+1.5%— | 105+1.5%— | 103+1.5%— | 102+12.2%— | 91+30.5%— | 69+23.2%— | 56—— | |
| Shares, weighted average (diluted) | 106+1.5%— | 105+1.5%— | 103+1.5%— | 102+12.2%— | 91+30.5%— | 69+23.2%— | 56—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 20−28.0%9.9% | 28−40.0%11.6% | 47+320%17.3% | 11r11−76.8%3.9% | 48+155%16.8% | 19+23.3%36.2% | 15—— | |
| Short-term investments | 83−34.5%41.0% | 127+4.0%52.9% | 122−43.7%45.4% | 216r216+4.3%75.4% | 207+1195%72.9% | 16—30.9% | — | |
| Receivables | 3.5−25.2%1.7% | 4.7−19.0%2.0% | 5.8−48.3%2.2% | 11r12+62.5%3.9% | 6.9+33.0%2.4% | 5.2—10.0% | — | |
| Inventory | 7.5−15.3%3.7% | 8.9−27.1%3.7% | 12+42.5%4.6% | 8.6r8.6+64.9%3.0% | 5.2+20.6%1.8% | 4.3—8.3% | — | |
| Other current assets | 4.3+18.6%2.1% | 3.6−7.5%1.5% | 3.9+19.7%1.5% | 3.3r2.8−1.5%1.1% | 3.3+230%1.2% | 1.0—1.9% | — | |
| Current assets | 118−31.1%58.5% | 172−9.7%71.7% | 190−24.6%70.9% | 252r252−6.7%88.0% | 270+498%95.2% | 45—87.4% | — | |
| Property, plant and equipment | 18−11.0%8.7% | 20−16.2%8.2% | 24−0.9%8.8% | 24r24+209%8.3% | 7.7+69.0%2.7% | 4.5—8.8% | — | |
| Right-of-use (leased) assets | 11+1.4%5.4% | 11−4.2%4.5% | 11+14.1%4.2% | 9.9r9.9+73.2%3.4% | 5.7+229%2.0% | 1.7—3.3% | — | |
| Other intangible assets | 0.7—0.3% | — | — | — | — | — | — | |
| Long-term investments | 53+46.9%26.0% | 36−16.7%14.9% | 43—16.0% | — | — | — | — | |
| Total assets | 203−15.4%100% | 239−10.7%100% | 268−6.4%100% | 287r287+0.9%100% | 284+449%100% | 52—100% | — | |
| Accounts payable | 1.4+3.2%0.7% | 1.4+82.8%0.6% | 0.7+154%0.3% | 0.3r0.5−84.0%0.1% | 1.8+104%0.6% | 0.9—1.7% | — | |
| Current liabilities | 14−9.6%7.0% | 16−11.6%6.6% | 18+15.7%6.7% | 15r15−1.2%5.4% | 16+34.5%5.5% | 12—22.4% | — | |
| Lease liabilities (non-current) | 16−4.0%8.1% | 17−4.4%7.2% | 18+12.7%6.7% | 16r16+209%5.6% | 5.2+318%1.8% | 1.2—2.4% | — | |
| Total liabilities | 31−6.6%15.3% | 33−8.0%13.9% | 36+10.5%13.5% | 33r33+54.0%11.4% | 21+14.4%7.5% | 19—35.8% | — | |
| Retained earnings | −261—−129% | −217—−90.6% | −176—−65.5% | −138r−138—−48.1% | −114—−40.2% | −95—−184% | — | |
| Shareholders' equity | 171−16.9%84.7% | 206−11.2%86.1% | 232−8.6%86.5% | 254r254−3.4%88.6% | 263r263+691%92.5% | 33+144%64.2% | 14—— | |
| Total liabilities and equity | 203−15.4%100% | 239−10.7%100% | 268−6.4%100% | 287r287+0.9%100% | 284+449%100% | 52—100% | — | |
| Shares outstanding | 107+1.0%— | 106+1.7%— | 104+1.5%— | 102+1.2%— | 101+30.8%— | 77—— | — | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 4.3+0.6%13.1% | 4.3+3.5%11.2% | 4.2+54.6%10.1% | 2.7r2.7+89.5%6.1% | 1.4+35.9%4.2% | 1.0+70.8%4.0% | 0.6—2.8% | |
| Share-based compensation | 9.2−29.6%27.9% | 13−6.4%33.9% | 14+18.9%33.9% | 12r12+47.7%26.6% | 8.0+222%23.5% | 2.5+41.1%9.4% | 1.8—8.1% | |
| Cash from operating activities | −34—−104% | −28—−71.5% | −22—−52.5% | −15r−15—−33.4% | −11—−31.5% | −8.8—−33.6% | −8.8—−40.7% | |
| Capital expenditure | −1.8—−5.4% | −1.7—−4.3% | −3.7—−9.0% | −18r−18—−41.7% | −3.8—−11.3% | −2.1—−7.9% | −1.3—−5.9% | |
| Acquisitions, net of cash acquired | −1.8—−5.4% | — | — | — | — | — | — | |
| Cash from investing activities | 26+274%78.5% | 6.9−87.4%17.9% | 55—133% | −25r−25—−56.1% | −195—−575% | −17−3748%−63.4% | 0.5—2.1% | |
| Shares issued | — | — | — | 2.9−94.4%6.6% | 52+81.4%153% | 29+132%109% | 12—57.0% | |
| Cash from financing activities | 0.7−68.1%2.0% | 2.1−4.1%5.3% | 2.1−25.8%5.2% | 2.9r2.9−98.8%6.5% | 235+712%693% | 29+135%110% | 12—56.9% | |
| Change in cash | −7.8—−23.7% | −19−153%−48.2% | 35—85.8% | −37r−37−226%−83.0% | 29+719%85.6% | 3.5−10.6%13.5% | 4.0—18.3% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 34−0.1%100% | 10+48.7%100% | 7.3−14.5%100% | 9.7−7.1%100% | 7.3*−16.0%100% | 6.8−16.4%100% | 8.5−18.4%100% | 10−8.4%100% | 8.7*−44.5%100% | 8.2—100% | 10—100% | 11—100% | 16r16*—100% | |
| Cost of revenue | 6.5−5.2%19.0% | 1.7+5.5%16.6% | 1.7+10.3%23.0% | 1.6+4.8%16.3% | 1.6*−29.4%22.1% | 1.6−17.2%23.4% | 1.5+2.1%17.9% | 1.5+6.7%14.4% | 2.3*+45.0%26.2% | 1.9—23.6% | 1.5—14.3% | 1.4—12.4% | 1.6r1.6*—10.0% | |
| Gross profit | 28+1.1%81.0% | 8.5+61.8%83.4% | 5.6−19.9%77.0% | 8.1−9.1%83.7% | 5.7*−11.3%77.9% | 5.2−16.1%76.6% | 7.0−21.8%82.1% | 8.9−10.5%85.6% | 6.4*−54.5%73.8% | 6.2—76.4% | 8.9—85.7% | 9.9—87.6% | 14r14*—90.0% | |
| Research and development | 14−35.2%41.7% | 2.9−45.9%28.3% | 4.3−32.2%58.5% | 3.9−34.7%40.0% | 3.3*−27.7%45.7% | 5.30.0%77.8% | 6.3+11.6%73.7% | 5.9−11.6%56.8% | 4.6*−21.0%53.1% | 5.3—65.1% | 5.6—53.9% | 6.7—58.9% | 5.8r5.8*—37.3% | |
| Selling and marketing | 15−33.7%42.2% | 4.2+7.1%41.5% | 3.4−41.9%46.3% | 3.4−39.8%35.5% | 3.5*−45.9%48.0% | 3.9−36.6%57.6% | 5.8−12.6%68.0% | 5.7−22.6%54.8% | 6.5*−10.1%74.5% | 6.2—76.0% | 6.6—63.4% | 7.4—64.9% | 7.2r7.2*—45.9% | |
| General and administrative | 25−15.4%73.5% | 6.6+8.7%64.5% | 7.3−10.2%99.8% | 6.0−30.0%61.8% | 5.5*−23.9%75.1% | 6.0−22.2%88.3% | 8.1+5.8%95.0% | 8.5+20.0%82.1% | 7.2*−10.9%82.9% | 7.7—94.9% | 7.6—73.2% | 7.1—62.6% | 8.1r8.1*—51.6% | |
| Operating expenses | 62−24.1%179% | 15−25.1%143% | 16−25.4%218% | 14−32.7%148% | 17*−12.4%232% | 19−4.5%284% | 21+1.5%249% | 21−4.6%204% | 19*−13.0%222% | 20—249% | 21—200% | 22—196% | 22r22*—142% | |
| Operating income | −34—−98.0% | −6.0—−59.5% | −10—−141% | −6.2—−64.1% | −11*—−154% | −14—−207% | −14—−167% | −12—−118% | −13*—−148% | −14—−172% | −12—−115% | −12—−108% | −8.1r−8.1*—−51.7% | |
| Interest and finance income | 5.7−28.2%16.6% | 1.3−26.2%12.6% | 1.4−27.4%18.7% | 1.4−29.4%14.9% | 1.6*−29.3%22.3% | 1.7−30.6%25.4% | 1.9−27.9%22.0% | 2.0−26.0%19.6% | 2.3*−18.2%26.5% | 2.5—30.6% | 2.6—24.9% | 2.7—24.2% | 2.8r2.8*—18.0% | |
| Other non-operating income (expense) | 5.7−28.2%16.6% | 1.3−26.2%12.6% | 1.4−27.4%18.7% | 1.4−29.4%14.9% | 1.6*−29.3%22.3% | 1.7−30.6%25.4% | 1.9−27.9%22.0% | 2.0−26.0%19.6% | 2.3*−18.2%26.5% | 2.5—30.6% | 2.6—24.9% | 2.7—24.2% | 2.8r2.8*—18.0% | |
| Income before tax | −28—−81.4% | −4.8—−46.9% | −8.9—−122% | −4.8—−49.2% | −9.6*—−131% | −12—−182% | −12—−145% | −10—−98.8% | −11*—−122% | −12—−142% | −9.4—−89.9% | −9.5—−84.0% | −5.3*—−33.7% | |
| Net income including minority interests | −28—−81.4% | −4.8*—−46.9% | −8.9*—−122% | −4.8—−49.2% | −9.6*—−131% | −12*—−182% | −12*—−145% | −10—−98.8% | −11*—−122% | −12*—−142% | −9.4*—−89.9% | −9.5—−84.0% | −5.3r−5.3*—−33.7% | |
| Net income attributable to shareholders | −28—−81.4% | −4.8—−46.9% | −8.9—−122% | −4.8—−49.2% | −9.6*—−131% | −12—−182% | −12—−145% | −10—−98.8% | −11*—−122% | −12—−142% | −9.4—−89.9% | −9.5—−84.0% | −5.3r−5.3*—−33.7% | |
| Earnings per share, basic | — | -0.05—— | -0.08—— | -0.04—— | — | -0.12—— | -0.12—— | -0.10—— | — | -0.11—— | -0.09—— | -0.09—— | — | |
| Earnings per share, diluted | — | -0.05—— | -0.08—— | -0.04—— | — | -0.12—— | -0.12—— | -0.10—— | — | -0.11—— | -0.09—— | — | — | |
| Shares, weighted average (basic) | 104−2.9%— | 104−2.9%— | 107+0.4%— | 107+0.9%— | — | 107+1.4%— | 106+1.7%— | 106+1.8%— | — | 105—— | 105—— | 104—— | — | |
| Shares, weighted average (diluted) | 104−2.9%— | 104−2.9%— | 107+0.4%— | 107+0.9%— | — | 107+1.4%— | 106+1.7%— | 106+1.8%— | — | 105—— | 105—— | 104—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 13—7.3% | 13+3.1%7.3% | 15−1.2%8.1% | 15−37.8%7.5% | 20−28.0%9.9% | 13−64.9%6.1% | 15−59.4%6.9% | 23+5.1%10.2% | 28−40.0%11.6% | 37—14.9% | 38—14.9% | 22—8.6% | 47—17.3% | |
| Short-term investments | 88—48.2% | 88−5.2%48.2% | 91−18.6%49.1% | 92−19.7%47.5% | 83−34.5%41.0% | 93−20.6%43.4% | 111−7.1%50.7% | 115−15.1%50.0% | 127+4.0%52.9% | 117—47.0% | 120—47.6% | 135—52.4% | 122—45.4% | |
| Receivables | 12—6.6% | 12+45.1%6.6% | 3.9−31.8%2.1% | 4.2−23.1%2.2% | 3.5−25.2%1.7% | 8.3+82.1%3.9% | 5.8+25.6%2.6% | 5.5−7.8%2.4% | 4.7−19.0%2.0% | 4.6—1.8% | 4.6—1.8% | 6.0—2.3% | 5.8—2.2% | |
| Inventory | 7.4—4.0% | 7.4−3.0%4.0% | 7.8−1.7%4.2% | 7.6−7.8%3.9% | 7.5−15.3%3.7% | 7.6−26.8%3.6% | 7.9−28.9%3.6% | 8.3−30.8%3.6% | 8.9−27.1%3.7% | 10—4.2% | 11—4.4% | 12—4.6% | 12—4.6% | |
| Other current assets | 3.8—2.1% | 3.8+25.9%2.1% | 3.7+23.3%2.0% | 4.2+14.3%2.2% | 4.3+18.6%2.1% | 3.0−27.3%1.4% | 3.0+15.3%1.4% | 3.7+14.6%1.6% | 3.6−7.5%1.5% | 4.1—1.7% | 2.6—1.0% | 3.2—1.2% | 3.9—1.5% | |
| Current assets | 125—68.3% | 125+0.0%68.3% | 121−15.3%65.7% | 123−21.1%63.2% | 118−31.1%58.5% | 125−27.9%58.4% | 143−18.5%65.2% | 156−12.8%67.7% | 172−9.7%71.7% | 173—69.5% | 176—69.8% | 179—69.3% | 190—70.9% | |
| Property, plant and equipment | 14—7.9% | 14−23.0%7.9% | 15−23.2%8.1% | 17−16.5%8.6% | 18−11.0%8.7% | 19−11.2%8.7% | 19−10.7%8.8% | 20−12.6%8.7% | 20−16.2%8.2% | 21—8.4% | 22—8.6% | 23—8.8% | 24—8.8% | |
| Right-of-use (leased) assets | 10—5.6% | 10−8.1%5.6% | 10−7.7%5.7% | 11−7.3%5.5% | 11+1.4%5.4% | 11+2.3%5.2% | 11+3.1%5.2% | 12+3.7%5.0% | 11−4.2%4.5% | 11—4.4% | 11—4.4% | 11—4.3% | 11—4.2% | |
| Goodwill | — | — | — | — | — | 3.6—1.7% | 3.7—1.7% | 3.9—1.7% | — | — | — | — | — | |
| Other intangible assets | 0.7—0.4% | 0.7+12.3%0.4% | 0.8+20.1%0.4% | 0.8+57.2%0.4% | 0.7—0.3% | 0.7—0.3% | 0.6—0.3% | 0.5—0.2% | — | — | — | — | — | |
| Long-term investments | 31—17.2% | 31−39.8%17.2% | 36−6.1%19.6% | 41+12.0%21.0% | 53+46.9%26.0% | 52+22.1%24.5% | 39−9.1%17.6% | 36−19.1%15.8% | 36−16.7%14.9% | 43—17.2% | 42—16.9% | 45—17.5% | 43—16.0% | |
| Total assets | 182—100% | 182−14.5%100% | 185−16.0%100% | 194−15.4%100% | 203−15.4%100% | 213−14.1%100% | 220−12.6%100% | 230−10.8%100% | 239−10.7%100% | 249—100% | 251—100% | 258—100% | 268—100% | |
| Accounts payable | 1.0—0.6% | 1.0−20.2%0.6% | 1.7+43.3%0.9% | 1.2−47.5%0.6% | 1.4+3.2%0.7% | 1.3−31.0%0.6% | 1.2+27.0%0.6% | 2.3+36.1%1.0% | 1.4+82.8%0.6% | 1.9—0.8% | 1.0—0.4% | 1.7—0.6% | 0.7—0.3% | |
| Current liabilities | 16—8.7% | 16−1.2%8.7% | 9.9−14.4%5.4% | 10−19.8%5.3% | 14−9.6%7.0% | 16−8.6%7.5% | 12−5.9%5.3% | 13−5.5%5.5% | 16−11.6%6.6% | 18—7.1% | 12—4.9% | 13—5.2% | 18—6.7% | |
| Lease liabilities (non-current) | 15—8.4% | 15−9.0%8.4% | 16−8.6%8.5% | 16−8.2%8.3% | 16−4.0%8.1% | 17−3.2%7.9% | 17−2.6%7.8% | 18−1.5%7.6% | 17−4.4%7.2% | 17—7.0% | 18—7.0% | 18—6.9% | 18—6.7% | |
| Total liabilities | 32—17.3% | 32−5.0%17.3% | 26−10.7%14.0% | 27−13.0%13.7% | 31−6.6%15.3% | 33−6.0%15.6% | 29−4.0%13.2% | 31−3.2%13.3% | 33−8.0%13.9% | 35—14.2% | 30—12.0% | 32—12.2% | 36—13.5% | |
| Retained earnings | −280—−153% | −280—−153% | −275—−149% | −266—−137% | −261—−129% | −252—−118% | −239—−109% | −227—−98.8% | −217—−90.6% | −206—−83.0% | −195—−77.4% | −185—−71.9% | −176—−65.5% | |
| Shareholders' equity | 151—82.7% | 151−16.3%82.7% | 159−16.8%86.0% | 168−15.8%86.3% | 171−16.9%84.7% | 180−15.5%84.4% | 191−13.8%86.8% | 199−11.9%86.7% | 206−11.2%86.1% | 213—85.8% | 221—88.0% | 226—87.8% | 232—86.5% | |
| Total liabilities and equity | 182—100% | 182−14.5%100% | 185−16.0%100% | 194−15.4%100% | 203−15.4%100% | 213−14.1%100% | 220−12.6%100% | 230−10.8%100% | 239−10.7%100% | 249—100% | 251—100% | 258—100% | 268—100% | |
| Shares outstanding | 103—— | 103−3.2%— | 106−0.4%— | 107+0.8%— | 107+1.0%— | 107+1.3%— | 107+1.7%— | 106+1.8%— | 106+1.7%— | 105—— | 105—— | 104—— | 104—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 3.9−7.9%11.5% | 0.9−16.9%8.6% | 1.0−11.8%13.1% | 1.0−4.5%10.8% | 1.1*+1.4%14.7% | 1.0−2.1%15.3% | 1.1−0.1%12.7% | 1.1−1.4%10.5% | 1.1*−4.1%12.2% | 1.1—13.1% | 1.1—10.4% | 1.1—9.8% | 1.1r1.1*—7.0% | |
| Share-based compensation | 4.0−65.9%11.5% | 1.0−50.7%9.5% | 1.2−67.0%16.0% | 1.1−62.5%11.8% | 0.7*−77.5%9.7% | 2.0−42.0%28.6% | 3.5−1.4%41.3% | 3.0+0.8%29.2% | 3.1*−12.3%36.1% | 3.4—41.3% | 3.6—34.2% | 3.0—26.6% | 3.6r3.6*—22.8% | |
| Cash from operating activities | −21—−61.2% | −5.5*—−54.2% | −4.7*—−64.1% | −8.2—−84.6% | −2.7*—−36.8% | −7.5*—−109% | −9.9*—−116% | −14—−139% | −7.8*−897%−90.0% | −4.4*—−53.8% | −4.8*—−46.4% | −11—−93.1% | 1.0r1.0*—6.3% | |
| Capital expenditure | −0.4—−1.2% | −0.1*—−0.6% | −0.1*—−0.9% | −0.1—−0.7% | −0.2*—−3.2% | −0.3*—−4.4% | −0.6*—−6.9% | −0.7—−6.3% | −0.1*—−1.7% | −0.4*—−5.0% | −0.3*—−2.8% | −0.8—−7.1% | −0.9r−0.9*—−5.8% | |
| Intangible assets bought | — | 0*—0.0% | 0*—0.0% | −0.2—−1.6% | — | — | — | — | — | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −1.8—−17.1% | — | — | — | — | — | |
| Cash from investing activities | 27+83.3%77.8% | 7.9*+51.3%77.4% | 6.6*+327%90.3% | 2.7−72.1%27.5% | 9.7*—133% | 5.2*+43.9%76.0% | 1.5*−92.1%18.1% | 9.5—91.7% | −1.7*—−19.2% | 3.6*—44.2% | 19*—186% | −14—−127% | −4.1r−4.1*—−26.4% | |
| Shares bought back | — | −4.0*—−39.6% | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | −5.3−654%−15.5% | −4.0*−28829%−39.6% | −1.4*−1022%−19.5% | 0.0−98.7%0.1% | 0.1*−74.5%1.4% | 0.0*−93.9%0.2% | 0.2*−78.4%1.8% | 0.4−45.5%3.7% | 0.4*−16.4%4.7% | 0.2*—2.8% | 0.7*—6.8% | 0.7—6.2% | 0.5*—3.1% | |
| Change in cash | 0.4—1.2% | −1.7*—−16.4% | 0.5*—6.7% | −5.5—−57.1% | 7.1*—97.2% | −2.3*—−33.0% | −8.2*−153%−95.9% | −4.5—−43.3% | −9.1*—−104% | −0.6*—−6.8% | 15*—146% | −24—−214% | −2.7r−2.7*—−17.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What MaxCyte, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product sales(total)$19 M57%-11%
- Licenses$12 M37%-25%
- Assay and other service revenue$2 M6.0%—
Business segments
- Cell Engineering Technology$33 M100%-14%
Countries and regions
- 🇺🇸 USA$21 M64%-18%
- Outside the United States(total)$12 M36%-7.1%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at MaxCyte, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 2 · Directors and officers 6 · Material agreement 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 acquisitions, $2 M paid where reported · 2 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| SeQure Inc | 2025 | — | $2 M | 100% | Annual report |
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at MaxCyte, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $118 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Electrical EngineerElectrical Engineers | 1 | $118 K |
Where: Rockville, MD 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $118 K | 1 |
| FY2025 | 3 | 3 | $135 K | 3 |
| FY2024 | 1 | 1 | $73 K | 1 |
| FY2023 | 1 | 1 | $93 K | 1 |
| FY2022 | 3 | 3 | $106 K | 3 |
| FY2020 | 1 | 1 | $110 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MaxCyte, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 34% of workforce | Restructuring planSEC 8-K | “The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged thro…” | Filing | |
| 15% of workforce | Restructuring planSEC 8-K | “The Plan is expected to result in a reduction of approximately 15% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged thro…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How MaxCyte, Inc. compares in Diagnostics and Research
- Market cap$156 M · higher than 29% of 110
- Revenue$33 M · higher than 24% of 123
- Net margin-81.4% · higher than 13% of 112
- Revenue growth-14.5% · higher than 18% of 89
- Price / sales4.5× · lower than 44% of 85
- Price / book0.9× · lower than 84% of 84
- FCF yield-23.2% · higher than 22% of 66
- 🇺🇸 Neuronetics, Inc.$162 M
- 🇮🇩 PT Prodia Widyahusada Tbk$119 M
- 🇺🇸 Anixa Biosciences, Inc.$117 M
- 🇨🇦 Spectral Medical Inc.$217 M
- 🇺🇸 Exagen Inc.$218 M
- 🇮🇳 Vimta Labs Limited$226 M
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| MaxCyte, Inc.🇺🇸 | $156 M | — | -81.4% | -14.5% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Neuronetics, Inc.$162 M
- PT Prodia Widyahusada Tbk$119 M
- Anixa Biosciences, Inc.$117 M
- Spectral Medical Inc.$217 M
- Exagen Inc.$218 M
- Vimta Labs Limited$226 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MaxCyte, Inc.? Verify and update this profile — free
Show MaxCyte, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.